Drugs / Chlorothiazide
Chlorothiazide
also known as
CHLOROTHIAZIDE SODIUM · Chlorothiazide sodium salt · Clorotiazida · Diuril · Hydrochlorothiazide impurity, chlorothiazide- · NSC-25693 · Saluric
Small molecule targets SLC12A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DIURIL | — | 1958-09-04 | fda.gov ↗ |
Trials 5
195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02546583 | Aug 2015 → Jan 2020 | heart failure | Yale University | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT00000484 | Apr 1966 → Jan 1979 | essential hypertension, heart disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT02606253 | Feb 2016 → Sep 2018 | heart failure | Vanderbilt University | Completed | Missed primary |
| Phase 4 | NCT05840536 | May 2014 → Oct 2015 | heart failure | Ochsner Health System | Withdrawn | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT03574857 Comparator | Jun 2018 → Jan 2021 | symptomatic heart failure | University of Virginia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorothiazide | “Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone” NCT00684489 ↗7“Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ |
| Known as | CHLOROTHIAZIDE SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | Chlorothiazide sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | Clorotiazida | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | Diuril | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | Hydrochlorothiazide impurity, chlorothiazide- | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | NSC-25693 | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Known as | Saluric | ChEMBL registry synonym — accepted as the source's own label CHEMBL842 ↗ |
| Action | Inhibit | “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL842 ↗ |
| Modality | Small molecule | — CHEMBL842 ↗ |
| Route | Intravenous | “IV Chlorothiazide” NCT02546583 ↗ |
| Target | SLC12A3 | “Thiazide-sensitive sodium-chloride cotransporter inhibitor” CHEMBL842 ↗ |